VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Saturday, January 3, 2026
Stock Comparison
AstraZeneca PLC vs Thermo Fisher Scientific Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisThermo Fisher Scientific Inc.
TMO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Thermo Fisher Scientific Inc.'s moat claims, evidence, and risks.
View TMO analysisComparison highlights
- Moat score gap: AstraZeneca PLC leads (71 / 100 vs 64 / 100 for Thermo Fisher Scientific Inc.).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Thermo Fisher Scientific Inc. has 4 segments (53.6% in Laboratory Products and Biopharma Services).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Strong vs Moderate.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Thermo Fisher Scientific Inc. has 8 across 3.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Thermo Fisher Scientific Inc.
Laboratory Products and Biopharma Services
Laboratory supplies distribution/market channel plus outsourced biopharma services (CDMO/CRO)
Global
Pharma & biotech; academic/government labs; industrial and clinical laboratories
Distributor/market channel and outsourced services provider
53.6%
Side-by-side metrics
Moat coverage
Shared moat types
AstraZeneca PLC strengths
Thermo Fisher Scientific Inc. strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Thermo Fisher Scientific Inc. segments
Full profile >Life Sciences Solutions
Oligopoly
Analytical Instruments
Oligopoly
Specialty Diagnostics
Oligopoly
Laboratory Products and Biopharma Services
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.